<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669861</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-744</org_study_id>
    <nct_id>NCT03669861</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Abatacept in IgG4-Related Disease</brief_title>
  <official_title>A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, single center, proof of concept clinical trial in subjects with active&#xD;
      IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be&#xD;
      enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept&#xD;
      (125mg) for 24 doses (24 weeks).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining informed consent, all screening procedures and tests establishing eligibility&#xD;
      will be performed on the initial screening visit. Subjects determined to be eligible at&#xD;
      screening will receive an initial subcutaneous dose of abatacept (125mg), which will be&#xD;
      continued weekly for a total of up to 24 doses (24 weeks). Steroid therapy must be tapered&#xD;
      off and discontinued over a 4 week period (taper must be completed no later than week 4).&#xD;
      Should patients be deemed to have worsening disease or failing therapy at 4 weeks then a&#xD;
      trial of steroids can be considered.&#xD;
&#xD;
      Subjects will return on weeks 1, 2, 4, 8, 12, 16, 20, and 24 while on treatment for their&#xD;
      injections, and for the scheduled safety and disease response assessments. Subjects will be&#xD;
      allowed to self-administer their injections at home. The full treatment period is 24 doses&#xD;
      given weekly for 24 weeks. Subjects who are not able to be tapered off corticosteroids or who&#xD;
      require reinstitution of corticosteroid therapy at any time during the study will be counted&#xD;
      as treatment failures, but may continue on study. Should the IgG4-RD responder index fail to&#xD;
      improve by 8 weeks or should there be development of new organ failure at 4 weeks, patient's&#xD;
      will be deemed treatment failure and can begin corticosteroid or alternative&#xD;
      immunosuppressive therapy at the Investigator's discretion. Those who require rituximab or&#xD;
      who require addition of other oral immunosuppressives will be counted as treatment failures&#xD;
      and will terminate the study.&#xD;
&#xD;
      All subjects completing the treatment period will have follow up visits off protocolized&#xD;
      treatment at 28 and 36 weeks. All adverse events (including serious adverse events (AEs) and&#xD;
      deaths) and use of concomitant medication information will be collected throughout the study&#xD;
      from screening through study termination. Subjects developing treatment-emergent adverse&#xD;
      events or clinically significant safety lab abnormalities will be followed until resolution&#xD;
      or until stabilization of the adverse events/abnormalities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Actual">November 10, 2020</completion_date>
  <primary_completion_date type="Actual">April 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Effect of weekly subcutaneous (SC) administration of abatacept on complete remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assess the effect of abatacept on disease response at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Response at Week 24</measure>
    <time_frame>disease response at 24 weeks</time_frame>
    <description>Percentage of patients achieving disease response at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Remission: Flares Over Time Per Subject</measure>
    <time_frame>24 weeks</time_frame>
    <description>number of disease flares per subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Serum IgG4 Concentration of Responders</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Serum IgG4 measured at baseline and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Serum IgE Concentration of Responders</measure>
    <time_frame>24 weeks</time_frame>
    <description>Serum IgE concentration was measured at baseline and Week 24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>IgG4-related Disease</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are male or female 18 years of age or older&#xD;
&#xD;
          2. Meet the American College of Rheumatology (ACR)/EULAR 2018 Classification Criteria for&#xD;
             IgG4-RD&#xD;
&#xD;
          3. Have active disease based on an IgG4-RD Responder Index (RI) ≥2 at screening with&#xD;
             disease manifestation in at least one organ system excluding lymph nodes at screening&#xD;
&#xD;
          4. May or may not have received prior IgG4-RD therapy&#xD;
&#xD;
          5. Must be willing to taper off any systemic corticosteroid therapy within 4 weeks of&#xD;
             first dose of trial drug.&#xD;
&#xD;
          6. Must be able and willing to discontinue any immunosuppressive agent at screening (e.g.&#xD;
             methotrexate, mycophenolate mofetil, 6-mercaptopurine, tacrolimus, cyclophosphamide or&#xD;
             azathioprine).&#xD;
&#xD;
          7. No history of severe allergic reactions to monoclonal antibodies.&#xD;
&#xD;
          8. Are able and willing to complete the entire study according to the study schedule.&#xD;
&#xD;
          9. Are willing to forego other forms of experimental treatment during the study.&#xD;
&#xD;
         10. Are able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or evidence of a clinically unstable/uncontrolled disorder, condition or&#xD;
             disease (including but not limited to cardiopulmonary, oncologic, renal, hepatic,&#xD;
             metabolic, hematologic or psychiatric) other than IgG4-RD that, in the opinion of the&#xD;
             Investigator, would pose a risk to patient safety or interfere with the study&#xD;
             evaluation, procedures or completion.&#xD;
&#xD;
          2. Malignancy within 5 years (except successfully treated in situ cervical cancer,&#xD;
             resected squamous cell or basal cell carcinoma of the skin, or prostate cancer with no&#xD;
             recurrence ≥3 years following prostatectomy).&#xD;
&#xD;
          3. Liver disease: Acute or chronic non-IgG4-related liver disease deemed sufficiently&#xD;
             severe to impair their ability to participate in the trial.&#xD;
&#xD;
          4. Uncontrolled disease: evidence of another uncontrolled condition, including drug and&#xD;
             alcohol abuse, which could interfere with participation in the trial according to the&#xD;
             protocol.&#xD;
&#xD;
          5. Presence of recurrent or chronic infections, defined as ≥3 infections requiring&#xD;
             antimicrobials over the past 6 months prior to screening.&#xD;
&#xD;
          6. Active infection requiring hospitalization or treatment with parenteral antimicrobials&#xD;
             within the 30 days prior to randomization.&#xD;
&#xD;
          7. Prior use of rituximab (or other B cell depleting agents) within 6 months of&#xD;
             enrollment unless B cells have been demonstrated to have repopulated.&#xD;
&#xD;
          8. Use of any investigational agent within 5 half-lives of the agent (or 6 months if the&#xD;
             half-life is unknown) prior to enrollment.&#xD;
&#xD;
          9. White blood cell count &lt; 2.5 x 103/µL.&#xD;
&#xD;
         10. Absolute neutrophil count (ANC) &lt; 1.0 x 103/µL.&#xD;
&#xD;
         11. IgG4-related renal disease with serum creatinine &gt;2.0 mg/dL.&#xD;
&#xD;
         12. Hemoglobin &lt; 10 g/dL.&#xD;
&#xD;
         13. Platelet count &lt; 75 x 109/L.&#xD;
&#xD;
         14. Known positive result for HIV I or II antibody, hepatitis B surface antigen, hepatitis&#xD;
             B core antibody or hepatitis C antibody.&#xD;
&#xD;
         15. Has received live vaccines within 4 weeks of enrollment.&#xD;
&#xD;
         16. Inability to communicate reliably with the investigator.&#xD;
&#xD;
         17. Patient is pregnant or breast feeding, or planning to become pregnant while enrolled&#xD;
             in the study, up to end of study (EOS) visit.&#xD;
&#xD;
         18. Positive pregnancy test at screening or during the study.&#xD;
&#xD;
         19. Subjects who do not agree to use medically acceptable methods of contraception.&#xD;
&#xD;
         20. Male patient with a pregnant partner who is not willing to use a condom during the&#xD;
             treatment and up to end of study (EOS)visit.&#xD;
&#xD;
         21. Known or suspected sensitivity to mammalian cell-derived products or any components of&#xD;
             the study drug.&#xD;
&#xD;
         22. History of alcohol and/or substance abuse within 12 months prior to screening.&#xD;
&#xD;
         23. Unable or unwilling to partake in follow-up assessments or required protocol&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital and Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <results_first_submitted>May 18, 2021</results_first_submitted>
  <results_first_submitted_qc>July 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stone, John H, M.D., M.P.H</investigator_full_name>
    <investigator_title>Director, Division of Rheumatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G4-Related Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data will be shared upon request - without personal health information - following completion of the analysis. Inquiries should be directed to the Principal Investigator.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03669861/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Concurrent glucocorticoid treatment was permitted but was required to be discontinued by week 4.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abatacept</title>
          <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Flare</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary endpoint is 24 weeks, because this is the duration of time patients were on active treatment. The protocol called for a final study visit at 36 weeks, three months after the patients discontinued their active treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Abatacept</title>
          <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD. Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks). The protocol called for a final study visit at 36 weeks, three months after the patients discontinued their active treatment, primarily for safety</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" lower_limit="40" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Serum IgG4</title>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="597" lower_limit="304" upper_limit="913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Serum IgE</title>
          <units>IU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="480.5" lower_limit="195" upper_limit="802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease activity: IgG4-RD Responder Index score</title>
          <description>Twenty-five domains are assessed in the IgG4-RD RI. If no disease activity is scored in any domain, then the overall score is 0 points (lowest possible value). Scoring refers to manifestations of disease activity present in the last 28 days&#xD;
Scoring:&#xD;
0 Normal or resolved&#xD;
Improved but still present&#xD;
New / Recurrence while patient is off treatment or unchanged from the previous visit*&#xD;
Worsened or new disease manifestation despite treatment&#xD;
Range of score= 0-75 Total score is 75 points (maximum possible score)</description>
          <units>points range 0-75</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" lower_limit="2" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BAS-Duration of IgG4-RD (months)</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" lower_limit="2" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of active organs affected</title>
          <units>count of number of organs involved</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Response</title>
        <description>Effect of weekly subcutaneous (SC) administration of abatacept on complete remission</description>
        <time_frame>24 weeks</time_frame>
        <population>The primary outcome, complete remission at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response</title>
          <description>Effect of weekly subcutaneous (SC) administration of abatacept on complete remission</description>
          <population>The primary outcome, complete remission at week 24</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Response</title>
        <description>Assess the effect of abatacept on disease response at week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>All 10 patients were treated initially with abatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response</title>
          <description>Assess the effect of abatacept on disease response at week 12</description>
          <population>All 10 patients were treated initially with abatacept</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Response at Week 24</title>
        <description>Percentage of patients achieving disease response at week 24</description>
        <time_frame>disease response at 24 weeks</time_frame>
        <population>disease response at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Response at Week 24</title>
          <description>Percentage of patients achieving disease response at week 24</description>
          <population>disease response at week 24</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Remission: Flares Over Time Per Subject</title>
        <description>number of disease flares per subject</description>
        <time_frame>24 weeks</time_frame>
        <population>Subjects with reported disease flare on treatment. Disease flare was defined as recurrence of disease activity or demonstration of a disease exacerbation such that additional therapy beyond the trial protocol was indicated</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Remission: Flares Over Time Per Subject</title>
          <description>number of disease flares per subject</description>
          <population>Subjects with reported disease flare on treatment. Disease flare was defined as recurrence of disease activity or demonstration of a disease exacerbation such that additional therapy beyond the trial protocol was indicated</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decline in Serum IgG4 Concentration of Responders</title>
        <description>Serum IgG4 measured at baseline and week 24</description>
        <time_frame>24 Weeks</time_frame>
        <population>serum IgG4 concentration can be used as a surrogate marker for disease activity</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Decline in Serum IgG4 Concentration of Responders</title>
          <description>Serum IgG4 measured at baseline and week 24</description>
          <population>serum IgG4 concentration can be used as a surrogate marker for disease activity</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decline in Serum IgE Concentration of Responders</title>
        <description>Serum IgE concentration was measured at baseline and Week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Serum IgE concentrations declined in all 6 patients (100%) who demonstrated a disease response with abatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Abatacept</title>
            <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Decline in Serum IgE Concentration of Responders</title>
          <description>Serum IgE concentration was measured at baseline and Week 24</description>
          <population>Serum IgE concentrations declined in all 6 patients (100%) who demonstrated a disease response with abatacept</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event monitoring (from time of study drug administration) to end of study (visit 10 (week 36) or safety follow up visit, if needed). Ten subjects were enrolled in the study between December 2018 and August 2019. Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug a nd that does not necessarily have a causal relationship with this treatment.</time_frame>
      <desc>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity/congenital anomaly. All Serious Adverse Events (SAEs) that occur following the subject's written consent to participate in the study through 30 days of discontinuation of dosing must be reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abatacept</title>
          <description>To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD&#xD;
Abatacept: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>Thrombocytopenia is a condition in which you have a low blood platelet count. Platelets (thrombocytes) are colorless blood cells that help blood clot. Platelets stop bleeding by clumping and forming plugs in blood vessel injuries</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>episcleritis</sub_title>
                <description>Episcleritis is inflammation of the tissue lying between the sclera (the tough, white, fiber layer covering the eye) and the conjunctiva (the membrane that lines the eyelid and covers the white of the eye).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial also comes with additional limitations, specifically the small number of patients, the lack of a comparator group, and the open-label design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>DRAI Director of Clinical Trials</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6176920668</phone>
      <email>JHSTONE@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

